# Budesonide in Patients With Immune Mediated Enteropathies

> **NCT03866538** · PHASE4 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Enteropathy
- Celiac Disease
- CVID Enteropathy
- Collagenous Sprue
- Autoimmune Enteropathy

## Interventions

- **DRUG:** Withdrawal of Oral Budesonide

## Key facts

- **NCT ID:** NCT03866538
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-10
- **Primary completion:** 2021-10-19
- **Final completion:** 2021-10-19
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study recruitment was difficult and not acheived
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866538, "Budesonide in Patients With Immune Mediated Enteropathies". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03866538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*